ClinicalTrials.gg
CompletedNCT03492437Updated Aug 7, 2023Results posted

Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate

A Phase 1 interventional study of Dabigatran Etexilate and Tepotinib in Healthy, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-07.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 44 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Carcinoma, Non-Small-Cell Lung by Merck KGaA, Darmstadt, Germany — 1 open to participants now, 4 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · Merck KGaA, Darmstadt, Germany.

Enrollment
30th of 34
20 · median 143
Started
2018
with 3 others
Phase 1
12 of 35
1 open now
Registered
24th of 35
by date

Among the 35 studies in Carcinoma, Non-Small-Cell Lung by Merck KGaA, Darmstadt, Germany, this one is the 30th largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2018, is one of 12 in phase 1, and was the 24th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 35 studies in Carcinoma, Non-Small-Cell Lung by Merck KGaA, Darmstadt, Germany is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 44 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Carcinoma, Non-Small-Cell Lung by Merck KGaA, Darmstadt, Germany, or all of them as a file.
02

Study summary

This study investigated the effect of Tepotinib on the pharmacokinetics (PK) of the p-glycoprotein (P-gp) probe substrate Dabigatran etexilate.

03

Conditions studied

  • Healthy

Keywords

  • Non-small cell lung cancer (NSCLC)
  • P-glycoprotein
  • Tepotinib
  • Dabigatran Etexilate
04

Who can participate

Ages eligible
18 Years to 44 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants of non-child bearing potential
  • Body weight between 50 to 100 kilogram (kg)
  • (BMI) between 18.5 and 29.9 kilogram per meter square (kg/m\^2)
  • A male participant must agree to use and to have his female partner of to use highly effective method of
  • Participant must have given written before any study-related activities
  • All values for hematology, coagulation, and biochemistry tests of blood and urinalysis are within the normal range. Minor (solitary) non- deviation(s) are allowed as judged by the Investigator
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Participation in a clinical study within 60 days prior to first drug administration
  • Whole blood donation or loss of > 450 milliliter (mL) within 60 days prior to first drug administration
  • Any surgical or medical condition, or any other significant disease that could interfere with the study objectives, conduct, or evaluation
  • Supine systolic blood pressure (SBP) greater than (>) 140 millimeter of mercury (mmHg) or less than (\<) 90 mmHg, diastolic blood pressure (DBP) > 90 or \< 50 mmHg, and pulse rate > 90 or \<50 beats per minute (bpm) at Screening and at admission on Day-1.
  • 12-Lead (ECG) showing a interval per Fridericia's formula (QTcF) > 450 milliseconds (ms), PR > 215 ms, or QRS > 120 ms (at Screening)
  • estimated (eGFR) \< 90 milliliter per minute (mL/min) (at Screening)
  • Participants with gall bladder removal or other relevant surgery of gastrointestinal tract
  • History of any
  • History of epilepsy
  • Ascertained or presumptive allergy/ to the active drug substance and/or
  • Participants who in the Investigator's judgment were perceived as having an increased risk of bleeding
  • Positive screen for alcohol or drugs of abuse (at Screening and Day -1)
  • Positive screen for surface antigen (HBsAg), virus antibody (anti-HCV), and 1 and 2 antibodies (HIV1/HIV2 antibodies) (at Screening)
  • Excessive consumption of xanthine-containing food or beverages before study drug administration until collection of last pharmacokinetic (PK) sample in each period (at Screening and Day -1)
  • Receipt of any prescription or nonprescription medication within 14 days or 5 half-lives, before study drug administration
  • Smoker or former smoker who stopped smoking less than 6 months before the time of the Screening Visit
  • Intake of grapefruit, Seville orange, cranberry or juices of these 3 fruits, or St. John's Wort, from 14 days prior to Day -1
  • Inability to communicate or cooperate with the Investigator
  • Other factors, which in the opinion of the Investigator may interfere with study conduct (at Screening and Day -1 of first Period only)
  • Legal incapacity or limited legal capacity
  • Participants kept in detention
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Dabigatran Etexilate

    Drug: Dabigatran Etexilate

  • Experimental
    Tepotinib + Dabigatran

    Drug: Dabigatran Etexilate · Drug: Tepotinib

Interventions

  • Participants received single oral dose of Dabigatran etexilate on Day 1 of Treatment period 1 and co-administration of Dabigatran with Tepotinib on Day 8 of Treatment period 2.

  • Participants received single oral dose of Tepotinib for 8 days in Treatment period 2.

06

What researchers measure

Primary outcomes

  1. Area Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast) at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Total Dabigatran

    AUC0-t was calculated according to the mixed log linear trapezoidal rule.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours Post-dose on Day 1 and Day 8

  2. Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Total Dabigatran

    AUC0-inf was calculated as AUC0-t plus (+) AUCextra. AUCextra represents the extrapolated part of AUC0-inf calculated by Clastpred/Lambda z, where Clastpred is the predicted plasma concentration at the last sampling time point, calculated from the log-linear regression line for Lambda z determination at which the measured plasma concentration is at or above Lower limit of quantification (LLOQ).

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours Post-dose on Day 1 and Day 8

  3. Maximum Observed Plasma Concentration (Cmax) of Total Dabigatran

    Cmax was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours Post-dose on Day 1 and Day 8

Secondary outcomes

  1. Time to Reach Maximum Plasma Concentration (Tmax) of Total Dabigatran

    Tmax is time to reach maximum observed plasma concentration obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours Post-dose on Day 1 and Day 8

  2. Elimination Half Life (t1/2) of Total Dabigatran

    Elimination Half Life (t1/2) was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours Post-dose on Day 1 and Day 8

  3. Apparent Clearance (CL/f) of Total Dabigatran

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours Post-dose on Day 1 and Day 8

  4. Apparent Volume of Distribution During Terminal Phase (Vz/f) of Total Dabigatran

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/f after oral dose was influenced by the fraction absorbed.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours Post-dose on Day 1 and Day 8

  5. Percentage of Area Under the Plasma Concentration-Time Curve From Time Tlast Extrapolated to Infinity (AUC0-inf) Obtained by Extrapolation (AUCextra%) of Total Dabigatran

    The AUC from time tlast extrapolated to infinity given as percentage of AUC0-inf. AUCextra% = (AUCextra /AUC0-inf)\*100.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours Post-dose on Day 1 and Day 8

  6. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    Adverse event (AE) was defined as any untoward medical occurrence in participants which does not necessarily have causal relationship with treatment. AE was any unfavorable and unintended sign (including abnormal laboratory finding), symptom/disease temporally associated with use of medicinal product, whether/not considered related to medicinal product. A serious adverse event (SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both serious TEAEs and non-serious TEAEs.

    Time frame: Screening up to Day 4 in Period 1; Day 1 up to Day 15 in Period 2

  7. Number of Participants With Clinically Significant Changes in Laboratory Values

    Number of participants with clinically significant change in laboratory values were reported. Clinical significance was decided by the investigator. Laboratory investigation included hematology, biochemistry, virology, drugs of abuse, hormones, urinalysis, and coagulation.

    Time frame: Screening up to Day 4 in Period 1; Day 1 up to Day 15 in Period 2

  8. Number of Participants With Clinically Significant Changes in 12-lead Electrocardiogram (ECG) Findings

    Number of participants with clinically significant change in 12-lead ECG were reported. Clinical significance was decided by the investigator. The 12-lead ECGs were recorded after the participant have rested for at least 5 minutes in supine position.

    Time frame: Screening up to Day 4 in Period 1; Day 1 up to Day 15 in Period 2

  9. Number of Participants With Clinically Significant Changes in Vital Signs

    Number of participants with clinically significant change in vital signs were reported. Clinical significance was decided by the investigator. Vital signs included body temperature, blood pressure, and pulse rate.

    Time frame: Screening up to Day 4 in Period 1; Day 1 up to Day 15 in Period 2

07

Results

Posted Aug 7, 2023

Participant flow

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneDabigatran EtexilateTepotinib + Dabigatran
Started200
Completed200
Not completed00
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneDabigatran EtexilateTepotinib + Dabigatran
Started020
Completed019
Not completed01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryArea Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast) at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Total Dabigatran

AUC0-t was calculated according to the mixed log linear trapezoidal rule.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours Post-dose on Day 1 and Day 8
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
Area Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast) at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Total Dabigatran
nanogram*hour per milliliter (ng*h/mL)Dabigatran EtexilateTepotinib + Dabigatran
Area Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast) at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Total Dabigatran461 ± 74.9709 ± 64.6
Statistical analysis
  • Dabigatran Etexilate vs Tepotinib + Dabigatran · Ratio of geometric least square mean: 151.38 · 90% CI 127.35 to 179.93
PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Total Dabigatran

AUC0-inf was calculated as AUC0-t plus (+) AUCextra. AUCextra represents the extrapolated part of AUC0-inf calculated by Clastpred/Lambda z, where Clastpred is the predicted plasma concentration at the last sampling time point, calculated from the log-linear regression line for Lambda z determination at which the measured plasma concentration is at or above Lower limit of quantification (LLOQ).

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours Post-dose on Day 1 and Day 8
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Total Dabigatran
ng*hr/mLDabigatran EtexilateTepotinib + Dabigatran
Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Total Dabigatran544 ± 32.8730 ± 61.8
Statistical analysis
  • Dabigatran Etexilate vs Tepotinib + Dabigatran · Ratio of geometric least square mean: 144.70 · 90% CI 122.89 to 170.39
PrimaryMaximum Observed Plasma Concentration (Cmax) of Total Dabigatran

Cmax was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours Post-dose on Day 1 and Day 8
Reported as:
Geometric mean · Nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Total Dabigatran
Nanogram per milliliter (ng/mL)Dabigatran EtexilateTepotinib + Dabigatran
Maximum Observed Plasma Concentration (Cmax) of Total Dabigatran54.5 ± 72.876.9 ± 61.8
Statistical analysis
  • Dabigatran Etexilate vs Tepotinib + Dabigatran · Ratio of geometric least square mean: 138.45 · 90% CI 121.59 to 157.65
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of Total Dabigatran

Tmax is time to reach maximum observed plasma concentration obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours Post-dose on Day 1 and Day 8
Reported as:
Median · Hour
Time to Reach Maximum Plasma Concentration (Tmax) of Total Dabigatran
HourDabigatran EtexilateTepotinib + Dabigatran
Time to Reach Maximum Plasma Concentration (Tmax) of Total Dabigatran3.00 (1.50 to 6.00)4.00 (2.00 to 6.00)
Statistical analysis
  • Dabigatran Etexilate vs Tepotinib + Dabigatran · Median difference (net): 0.5 · 90% CI -0.3 to 1.0
SecondaryElimination Half Life (t1/2) of Total Dabigatran

Elimination Half Life (t1/2) was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours Post-dose on Day 1 and Day 8
Reported as:
Geometric mean · Hour
Elimination Half Life (t1/2) of Total Dabigatran
HourDabigatran EtexilateTepotinib + Dabigatran
Elimination Half Life (t1/2) of Total Dabigatran8.18 ± 12.97.81 ± 13.5
SecondaryApparent Clearance (CL/f) of Total Dabigatran

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours Post-dose on Day 1 and Day 8
Reported as:
Geometric mean · Liter per hour (L/h)
Apparent Clearance (CL/f) of Total Dabigatran
Liter per hour (L/h)Dabigatran EtexilateTepotinib + Dabigatran
Apparent Clearance (CL/f) of Total Dabigatran138 ± 32.8103 ± 61.8
SecondaryApparent Volume of Distribution During Terminal Phase (Vz/f) of Total Dabigatran

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/f after oral dose was influenced by the fraction absorbed.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours Post-dose on Day 1 and Day 8
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution During Terminal Phase (Vz/f) of Total Dabigatran
LiterDabigatran EtexilateTepotinib + Dabigatran
Apparent Volume of Distribution During Terminal Phase (Vz/f) of Total Dabigatran1627 ± 34.71157 ± 58.4
SecondaryPercentage of Area Under the Plasma Concentration-Time Curve From Time Tlast Extrapolated to Infinity (AUC0-inf) Obtained by Extrapolation (AUCextra%) of Total Dabigatran

The AUC from time tlast extrapolated to infinity given as percentage of AUC0-inf. AUCextra% = (AUCextra /AUC0-inf)\*100.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours Post-dose on Day 1 and Day 8
Reported as:
Geometric mean · percentage of AUC0-inf
Percentage of Area Under the Plasma Concentration-Time Curve From Time Tlast Extrapolated to Infinity (AUC0-inf) Obtained by Extrapolation (AUCextra%) of Total Dabigatran
percentage of AUC0-infDabigatran EtexilateTepotinib + Dabigatran
Percentage of Area Under the Plasma Concentration-Time Curve From Time Tlast Extrapolated to Infinity (AUC0-inf) Obtained by Extrapolation (AUCextra%) of Total Dabigatran3.03216 ± 55.12492.3654 ± 63.8621
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

Adverse event (AE) was defined as any untoward medical occurrence in participants which does not necessarily have causal relationship with treatment. AE was any unfavorable and unintended sign (including abnormal laboratory finding), symptom/disease temporally associated with use of medicinal product, whether/not considered related to medicinal product. A serious adverse event (SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both serious TEAEs and non-serious TEAEs.

Time frame:
Screening up to Day 4 in Period 1; Day 1 up to Day 15 in Period 2
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsDabigatran EtexilateTepotinib + Dabigatran
Treatment-emergent Adverse Events (TEAEs)415
Serious TEAEs00
SecondaryNumber of Participants With Clinically Significant Changes in Laboratory Values

Number of participants with clinically significant change in laboratory values were reported. Clinical significance was decided by the investigator. Laboratory investigation included hematology, biochemistry, virology, drugs of abuse, hormones, urinalysis, and coagulation.

Time frame:
Screening up to Day 4 in Period 1; Day 1 up to Day 15 in Period 2
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Laboratory Values
ParticipantsDabigatran EtexilateTepotinib + Dabigatran
Number of Participants With Clinically Significant Changes in Laboratory Values00
SecondaryNumber of Participants With Clinically Significant Changes in 12-lead Electrocardiogram (ECG) Findings

Number of participants with clinically significant change in 12-lead ECG were reported. Clinical significance was decided by the investigator. The 12-lead ECGs were recorded after the participant have rested for at least 5 minutes in supine position.

Time frame:
Screening up to Day 4 in Period 1; Day 1 up to Day 15 in Period 2
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in 12-lead Electrocardiogram (ECG) Findings
ParticipantsDabigatran EtexilateTepotinib + Dabigatran
Number of Participants With Clinically Significant Changes in 12-lead Electrocardiogram (ECG) Findings00
SecondaryNumber of Participants With Clinically Significant Changes in Vital Signs

Number of participants with clinically significant change in vital signs were reported. Clinical significance was decided by the investigator. Vital signs included body temperature, blood pressure, and pulse rate.

Time frame:
Screening up to Day 4 in Period 1; Day 1 up to Day 15 in Period 2
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Signs
ParticipantsDabigatran EtexilateTepotinib + Dabigatran
Number of Participants With Clinically Significant Changes in Vital Signs00

Adverse events

Collected over Screening up to Day 4 in Period 1; Day 1 up to Day 15 in Period 2. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dabigatran Etexilate0/20 (0%)0/20 (0%)4/20 (20%)
Tepotinib + Dabigatran0/20 (0%)0/20 (0%)15/20 (75%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventDabigatran EtexilateTepotinib + Dabigatran
DiarrhoeaGastrointestinal disorders1/2011/20
Abdominal pain upperGastrointestinal disorders0/207/20
NauseaGastrointestinal disorders0/206/20
FlatulenceGastrointestinal disorders0/203/20
Abdominal painGastrointestinal disorders0/202/20
Faeces softGastrointestinal disorders0/202/20
Blood creatine phosphokinase increasedInvestigations0/202/20
HeadacheNervous system disorders2/202/20
Abdominal discomfortGastrointestinal disorders0/201/20
DyspepsiaGastrointestinal disorders0/201/20

Baseline characteristics

Age, Continuous
Age, Continuous(Years)All Participants
Mean33 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female1
Male19
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino0
Not Hispanic or Latino20
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White19
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Nuvisan GmbH
    Neu-Ulm, 89231, Germany
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Aug 2018, 3 months.

Results were first posted in Aug 2023, 4 years 11 months after primary completion.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 3 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2018
First posted
Apr 10, 2018
StartActual
May 17, 2018
Primary completionActual
Aug 27, 2018
CompletionActual
Aug 27, 2018
Results first posted
Aug 7, 2023
Last update
Aug 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03492437
Responsible party
Sponsor
First posted
Apr 10, 2018
Start date
May 17, 2018
Primary completion
Aug 27, 2018
Completion
Aug 27, 2018
Results posted
Aug 7, 2023
Last update
Aug 7, 2023

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabigatran

Start the discussion